Small Molecules VS CAR-T In CLL

By the time CAR-T arrived in CLL, the disease had already been transformed by BTK inhibitors and venetoclax. TRANSCEND CLL 004 showed 18% CR in BTKi/venetoclax-refractory disease. Sarah Mitchell and James Carter explore why CLL is harder for CAR-T, where it still has a role - especially in Richter's transformation - and why timing of T cell collection matters.

Moving CAR-T To Earlier Myeloma Lines

Ciltacabtagene autoleucel achieved a 97% overall response rate and 67% complete response in triple-class refractory multiple myeloma - numbers not thought achievable a decade ago. CARTITUDE-4 has now moved it to the second line. Sarah Mitchell and James Carter cover the BCMA story, the new targets, and the resistance mechanisms driving the next generation.

EASL Congress 2026: Key Trials to Watch in Liver Disease Management

EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.

Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies

EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.

Semaglutide For Obese Heart Failure Patients

More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating the metabolic environment is the new paradigm for HFpEF.

Diabetes Drugs For Stiff Heart Failure

Heart failure with preserved ejection fraction accounts for more than half of all HF diagnoses. For two decades every major drug trial failed. Then SGLT2 inhibitors changed everything - twice. Sarah Mitchell and James Carter explain why HFpEF was so hard, and what finally worked.

The GLP-1 Muscle Loss Dilemma

GLP-1 receptor agonists drive significant lean mass loss alongside fat loss — a concern that may undermine long-term metabolic health and physical function. Sarah Mitchell and James Carter examine the muscle loss evidence, the role of resistance training, and emerging strategies to preserve lean tissue during weight loss.

The Velvet Rope Of Weight Loss Drugs

Semaglutide and tirzepatide produce results that obesity medicine has never seen before — but demand vastly outstrips supply, cost remains prohibitive for many, and prescribing criteria vary widely between health systems. Sarah Mitchell and James Carter examine who is getting GLP-1 therapy and why equity matters.

Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's

Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.

CGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients

CGRP-targeted therapies are effective for migraine prevention, but cardiovascular safety data is limited in patients with established vascular disease.